我妈妈08年11月易耐药,现已打一个疗程的力比泰+顺铂.效果不理想,恳请大家的帮助!!

wangfeifei

你妈妈用力比泰+顺铂 副作用大吗？

无香

既然没有很好的其它解决办法,就是鞘内治疗效果可能不会很大,我觉的也 有必要尝试一下,毕竟没有好办法.只是腰穿,痛苦性也不大.老家主治做了几例鞘内,据她说反馈还可以.

拿什么拯救你

你可以试试特罗凯，我姐姐就是这样，07年10月份发现时就有脑转，做了全脑放疗后开始吃易，前段时间易耐药后，脑转加重，差点丢了性命，我在“爱之家”有帖子记录，然后我们开始服用秘鲁版的特罗凯，两天后就见效，现在头已经不疼了，身体也逐步恢复了。
如果你还没有其它办法，我劝你一试，毕竟秘鲁版的还不是太贵，一个月才4500,我们还能承受的起。

172006mama

我妈妈吃易也有半年了,这个月的CT显示已经耐药,我想先换特罗凯试下,想问楼上的你的购买途径,先谢了.我的QQ476020469

cloud

楼主你妈妈的情况和我妈妈的几乎相同,我妈妈也是头痛,增强MIR查不出病灶.医生怀疑脑膜转移.建议我们全脑放疗.我们现在把易换成了特,效果还不错，头痛的症状减轻,但是眼睛模糊,不知道是脑转造成的，还是特的副作用。

潘朵朵

楼上的用的是正版的特还是秘鲁版的，我爸爸也是脑转，易瑞沙耐药，我也打算用特，询问下购买途径，谢谢

jimmy112199

试试蒂清加反映停吧，这是文献

Cancer. 2005 Jun 15;103:2590-7 15861414  [Cited: 1]     

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
蒂清加反映停治疗来自黑色素癌的脑转移瘤的二期研究
   
Wen-Jen Hwu , Eric Lis , Jennifer H Menell , Katherine S Panageas , Lynne A Lamb , Janene Merrell , Linda J Williams , Susan E Krown , Paul B Chapman , Philip O Livingston , Jedd D Wolchok , Alan N Houghton
BACKGROUND: Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases. METHODS: Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years). The primary end point was tumor response in the brain assessed every 8 weeks.患者经病理证实的转移性黑素瘤和可衡量的脑转移瘤，收到了蒂清（ 75MG，每天2次，6周，然后休息2周） ，另加伴（反映停
200毫克/天逐步升级至400毫克/天，--对患者< 70岁，或100毫克/天逐步升级至250毫克/天，--对患者>= 70岁）
。主要终点是肿瘤在大脑中反应，每8周评估一次)(RESULTS: Twenty-six patients with a median age of 60 years were treated. All patients had progressive brain metastases: 16 were symptomatic and 25 had extensive extracranial metastases. Eight patients had received whole-brain radiotherapy, 4 had received stereotactic radiotherapy, and 8 had received craniotomy with resection of hemorrhagic lesions. Fifteen patients completed > or = 1 cycle (median, 1 cycle; range, 0-4 cycles), and 11 discontinued treatment before completing 1 cycle (7 for intracranial hemorrhage, 2 for pulmonary embolism, 1 for deep vein thrombosis, and 1 for Grade 3 rash). Of 15 patients assessable for response, 3 had a complete or partial response (12% intent to treat) and 7 had minor response or stable disease in the brain. However, 5 of these 10 patients had disease progression at extracranial sites. The median survival period was 5 months for all 26 patients and 6 months for the 15 assessable patients. CONCLUSIONS: Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma.
Mesh-terms: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; Brain Neoplasms, drug therapy; Brain Neoplasms, secondary; Dacarbazine, administration & dosage; Dacarbazine, analogs & derivatives; Disease-Free Survival; Female; Humans; Male; Melanoma, drug therapy; Melanoma, secondary; Middle Aged; Neoplasm Staging; Research Support, Non-U.S. Gov't; Skin Neoplasms, drug therapy; Skin Neoplasms, pathology; Survival Rate; Thalidomide, administration & dosage; Treatment Outcome;